ADCs combine antibodies with drug payloads for targeted therapy, but complex manufacturing requires monitoring CQAs across multiple entities.
Scientists at the Institute of Science Tokyo (Science Tokyo) have successfully realized the highly selective asymmetric 1,6 ...
Early-phase oncology trials carry substantial scientific and commercial risk in cancer drug development. Getting them right ...
Discover how antibody-drug conjugates (ADCs) are transforming treatment strategies for gastrointestinal cancers, enhancing ...
Q4 2025 Earnings Call February 10, 2026 4:30 PM ESTCompany ParticipantsJacquie Ross - Senior Vice President of Treasury ...
Q2 2026 Earnings Call February 4, 2026 9:00 AM ESTCompany ParticipantsDavid Clair - VP of Investor Relations & ...
Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.
The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Henry Boot PLC - Sheffield, England-based construction and property ...
AstraZeneca's $15 billion pledge to its China operations highlights the country's advantages. But other regions are also hoping to host more clinical studies.
Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.
The key alterations sought are FGFR3 activating mutations or fusions/rearrangements (“susceptible” alterations), for potential use of the FGFR inhibitor erdafitinib (Balversa), and HER2 IHC expression ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results